Maureen F. Zakowski

Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer.

William Pao, Marc Ladanyi, Vincent A. Miller, 2006 .

Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features?

Michelle S. Ginsberg, M. Zakowski, M. Ginsberg, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

William Pao, Marc Ladanyi, Vincent A. Miller, 2013, Clinical Cancer Research.

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

William Pao, Martin Peifer, Ronglai Shen, 2009, PloS one.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

William Pao, Marc Ladanyi, Vincent A. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Marc Ladanyi, Natasha Rekhtman, B. Reva, 2013, Molecular Cancer Therapeutics.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

Chris Sander, William Pao, Stephen Broderick, 2009, Oncogene.

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Ronglai Shen, Marc Ladanyi, M. Ladanyi, 2012, Clinical Cancer Research.